Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (101-110 of 212) with videos related to

Pageof 22
Sort By:
Biorxiv : the Preprint Server for Biology|October 17, 2024
Decoding Spatial Tissue Architecture: A Scalable Bayesian Topic Model for Multiplexed Imaging AnalysisXiyu Peng, James W Smithy, Mohammad Yosofvand, et al.
Research Square|June 17, 2024
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation StudyMargaret K Callahan, Harriet Kluger, Michael A Postow, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Pigment Cell & Melanoma Research|July 3, 2024
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumabSarah E Lochrin, Darren J Buonocore, Robert J Young, et al.
The Oncologist|February 12, 2020
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of LiteratureKarmela Kim Chan, Cynthia Magro, Alexander Shoushtari, et al.
Cancer Research Communications|November 6, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and TrametinibPaul B Chapman, Mark Klang, Michael A Postow, et al.
British Journal of Haematology|June 27, 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterJustin M Watts, Ashwin Kishtagari, Meier Hsu, et al.
Oncoimmunology|January 4, 2018
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialDavid J Chung, Richard D Carvajal, Michael A Postow, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
Pageof 22

Showing results (101-110 of 212) with videos related to

Sort By:
Pageof 22
Biorxiv : the Preprint Server for Biology|October 17, 2024
Decoding Spatial Tissue Architecture: A Scalable Bayesian Topic Model for Multiplexed Imaging AnalysisXiyu Peng, James W Smithy, Mohammad Yosofvand, et al.
Research Square|June 17, 2024
Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancerJuan C Osorio, David A Knorr, Polina Weitzenfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation StudyMargaret K Callahan, Harriet Kluger, Michael A Postow, et al.
Journal of the National Cancer Institute|January 2, 2017
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + IpilimumabClaire F Friedman, Varina Clark, Andrew V Raikhel, et al.
Pigment Cell & Melanoma Research|July 3, 2024
Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumabSarah E Lochrin, Darren J Buonocore, Robert J Young, et al.
The Oncologist|February 12, 2020
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of LiteratureKarmela Kim Chan, Cynthia Magro, Alexander Shoushtari, et al.
Cancer Research Communications|November 6, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and TrametinibPaul B Chapman, Mark Klang, Michael A Postow, et al.
British Journal of Haematology|June 27, 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer CenterJustin M Watts, Ashwin Kishtagari, Meier Hsu, et al.
Oncoimmunology|January 4, 2018
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialDavid J Chung, Richard D Carvajal, Michael A Postow, et al.
Cancers|May 14, 2022
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced MelanomaKrisztian Homicsko, Reinhard Dummer, Christoph Hoeller, et al.
Pageof 22